

**Anti-EGFL7 Reference Antibody (parsatuzumab)
Recombinant Antibody
Catalog # APR10148****Specification**

Anti-EGFL7 Reference Antibody (parsatuzumab) - Product Information


Application	FC, Kinetics, Animal Model
Primary Accession	Q9UHF1
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	148.22 KDa

Anti-EGFL7 Reference Antibody (parsatuzumab) - Additional Information**Target/Specificity**
EGFL7**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-EGFL7 Reference Antibody (parsatuzumab) - Protein Information****Name** EGFL7**Synonyms** MEGF7**Function**
Regulates vascular tubulogenesis in vivo. Inhibits platelet- derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis.**Cellular Location**
Secreted, extracellular space**Anti-EGFL7 Reference Antibody (parsatuzumab) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-EGFL7 Reference Antibody (parsatuzumab) - Images



Anti-EGFL7 Reference Antibody (parsatuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-EGFL7 Reference Antibody (parsatuzumab) is more than 91.58%, determined by SEC-HPLC.